Plant
Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology
Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders
Biopharma Layoff Tracker 2024: uniQure, Vir, Arbutus, and More Cut Staff
biopharma layoffs, uniQure, Vir, Arbutus, biotech industry, job cuts, restructuring initiatives
Montara Therapeutics Launches with $8M to Develop Safer Neurological Therapeutics
Montara Therapeutics, neurological therapeutics, BrainOnly platform, seed funding, safer treatments
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
Ginkgo Bioworks to Lay Off Up to 400 Employees Amid Cost-Cutting Measures
Ginkgo Bioworks, layoffs, cost-cutting, biosecurity, cell programming, workforce reduction
GenScript ProBio Launches New Gene Therapy Production Plant in New Jersey
GenScript ProBio, Gene Therapy, Production Plant, New Jersey, CDMO, Biotech
GSK Faces Major Setback in Zantac Litigation as Judge Allows Over 70,000 Lawsuits to Proceed
GSK, Zantac, Lawsuits, Cancer, Delaware Court, Judge Vivian Medinilla, Ranitidine, NDMA, Pharmaceuticals
ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology
ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression
Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges
Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition